This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Hope S. Maki, MD; James L. Hoehn, MD

Arch Surg. 1989;124(3):377-380.

Abstract
• A retrospective chart review was conducted to determine the prognostic effect of estrogen receptor (ER) protein in patients with node-negative operable breast cancer. One hundred nine patients with breast cancer whose tumors underwent ER analysis and whose lymph node negativity was established histologically were studied. Based on life-table analysis, the overall survival at six years was 92.7% for ER-positive patients, 95.3% for ER-negative patients, and 94.4% for ER-borderline patients. The disease-free survival was 83.3%, 92.8%, and 71.4%, respectively. Survival and diseasefree survival were also correlated to menopausal status. The difference in survival was not statistically significant at six years. We conclude that in node-negative primary operable breast cancer, ER status should not be used as a discriminant for adjuvant treatment.

(Arch Surg 1989;124:377-380)

Author Affiliations
From the Department of Surgery, Marshfield (Wise) Clinic and Marshfield Medical Research Foundation.

Footnotes
Accepted for publication Feb 18, 1988.

Reprint requests to Department of Surgery, Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI 54449 (Dr Hoehn).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?